Q-omics provides the consensus-scored TRAV12-2 profile across patient tissues and cancer cell-line models. TRAV12-2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRAV12-2 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, TRAV12-2 RNA expression shows 14,749 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, KIRC, and DLBC as cancer lineages where TRAV12-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV12-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV12-2 survival associations across molecular data types. TRAV12-2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV12-2 RNA expression–survival associations across cancer types. High TRAV12-2 expression shows favorable associations in HNSC, SKCM, CESC, BRCA, OV and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRAV12-2 RNA expression.
This table summarizes TRAV12-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV12-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV12-2 shows lower tumor expression in COAD, BLCA, LUSC and UCEC and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher TRAV12-2 RNA expression in tumor versus normal tissue (log2 FC = +1.422, t-test p < 0.001).
This table shows molecular features associated with TRAV12-2 in patient tissues and cancer cell lines. In patient samples, TRAV12-2 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAV12-2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
